The Intellectual Property & Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, today announced a collaboration with Orion Bionetworks to further the understanding of multiple sclerosis (MS) and advance the development of new therapies by generating predictive models of patient stratification and drug targets.
Orion Bionetworks is an alliance of leading organizations in patient care, computational modeling, translational research, and patient advocacy dedicated to transforming the study of brain disorders and accelerating the discovery of new therapies and the search for cures. In this project focused on advancing the understanding of the underlying biology of MS, the members of the alliance will combine their expertise and assets including biomarkers, disease system biology, high performance computing information technology and big data analytics to integrate and interpret clinical, molecular, imaging and real-world patient data to develop new predictive models for the disease.
"We are pleased to welcome Thomson Reuters, which brings unique modeling capabilities that will help advance our shared goal of accelerating the search for cures for MS," said Magali Haas, founder and chief executive officer of Orion Bionetworks. "This collaboration further underscores the importance of building a robust computational modeling community with diverse expertise and assets to help realize the promise of predictive modeling in disease research."